Citatuzumab bogatox  (Synonyms: VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A)

Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models^[1][2][3].

Citatuzumab bogatox (0-100 nM; 5 days) inhibits growth of NIH:OVCAR-3 and CAL-27 cells, with IC₅₀s both are 3 nM^[1].
Citatuzumab bogatox internalizes into the cytoplasm of EpCAM-expressing cells and then the released Bouganin inhibits protein synthesis by inactivation of ribosome and leading to apoptosis of the cancer cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Citatuzumab bogatox (10, 20 mg/kg; i.v./i.p.) inhibits growth of tumor in mice^[1].
Citatuzumab bogatox (10, 20 mg/kg) are well tolerated by mice without any significant weight loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

945228-49-9

[Citatuzumab bogatox]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Fab-G1-kappa

• [1]. Cizeau J, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009 Jul-Aug;32(6):574-84.  [Content Brief]

  [2]. Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18(9):857-868.  [Content Brief]

  [3]. Bruce VJ, et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications. Chembiochem. 2016 Oct 17;17(20):1892-1899.  [Content Brief]